Generic Medicine Info
Indications and Dosage
Adult: Initially, 2 mg once daily, may increase after 3-4 wk to 4 mg/day. Max: 6 mg/day.
Hepatic Impairment
Severe: Reduce dose.
May be taken with or without food.
Use w/in 1 mth of MI; patients w/ aortic stenosis.
Special Precautions
Patients w/ pre-existing SA and AV nodes abnormalities, congenital or acquired QT prolongation, poor cardiac reserve. Hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Headache, dizziness, palpitations, tachycardia, flushing, abdominal discomfort, nausea, rash, erythema, pruritus, polyuria, asthenia, oedema, increased blood alkaline phosphatase.
Symptoms: Prolonged peripheral vasodilation associated w/ hypotension and tachycardia, bradycardia or prolonged AV conduction. Management: Symptomatic and supportive treatment.
Drug Interactions
Additive effect w/ diuretics, ACE inhibitors and β-blockers. May increase plasma level w/ cimetidine. Metabolism may be affected by CYP3A4 inhibitors (e.g. itraconazole) and inducers (e.g. rifampicin). May attenuate antihypertensive effect w/ corticoids or tetracosactide.
Food Interaction
May alter bioavailability w/ grapefruit juice.
Description: Lacidipine is a potent dihydropyridine Ca antagonist mainly selective for Ca channels in the vascular smooth muscle. It dilates peripheral arterioles resulting in reduced peripheral vascular resistance and BP.
Absorption: Rapidly but poorly absorbed from the GI tract. Absolute bioavailability: Approx 10%. Time to peak plasma concentration: 30-150 min.
Distribution: Plasma protein binding: >95%.
Metabolism: Undergoes hepatic metabolism via CYP3A4 isoenzyme.
Excretion: Via faeces (approx 70%) and urine (remaining dose). Terminal elimination half-life: 13-19 hr.
Store below 30°C.
MIMS Class
Anon. Lacidipine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc.

Buckingham R (ed). Lacidipine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press.

Joint Formulary Committee. Lacidipine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press.

Disclaimer: This information is independently developed by MIMS based on Lacidipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in